Soleno Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Soleno Therapeutics generated cash of -$24,940,000, which is less than the previous year. Cash used in financing activities reached the amount of $180,019,000 last year. Net change in cash is therefore $155,079,000.
Cash Flow
| 2014 | -4.48M | -30.68K | 11.20M |
|---|---|---|---|
| 2015 | -10.29M | -1.32M | 9.15M |
| 2016 | -13.49M | -38.68K | 10.76M |
| 2017 | -9.94M | 378.78K | 23.94M |
| 2018 | -11.68M | -180K | 17.82M |
| 2019 | -17.37M | 528K | 14.48M |
| 2020 | -25.22M | -7K | 53.72M |
| 2021 | -27.77M | -22K | -128K |
| 2022 | -20.78M | -13K | 14.09M |
| 2023 | -24.94M | 0 | 180.01M |
SLNO Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 14.60M | 21.30M | 49.22M | 20.73M | 23.09M | 17.13M | 2.72M | 5.49M | 7.95M | 1.26M |
Operating activities | ||||||||||
Net income | -38.98M | -24.06M | -30.91M | -24.63M | -30.77M | -11.84M | -12.07M | -12.06M | -15.90M | -13.87M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 1.95M | 1.96M | 1.96M | 1.95M | 1.95M | 1.96M | 1.61M | 131.64K | 108.22K | 28.51K |
Stock-based compensation expense | 5.94M | 2.53M | 3.27M | 1.5M | 825K | 0 | 880.03K | 871.27K | 942.36K | 345.43K |
| Deferred income tax benefit | 5.94M | 2.53M | 3.27M | 1.5M | 825K | 0 | 880.03K | 871.27K | 942.36K | 345.43K |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 64K | 0 | 0 | 22.79K | -156.12K | 149.60K |
Inventories | 0 | 0 | 0 | 0 | -64K | 0 | 0 | -109.38K | -441.67K | -109.33K |
Accounts payable | 1.37M | -1.47M | -235K | 1.49M | 1.06M | 249K | 190.63K | -149.16K | 211.94K | 353.89K |
Cash generated by operating activities | -24.94M | -20.78M | -27.77M | -25.22M | -17.37M | -11.68M | -9.94M | -13.49M | -10.29M | -4.48M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | -500K | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | 0 | -13K | -22K | -7K | -21K | -8K | -2.56K | -38.68K | -305.77K | -30.68K |
Acquisitions Net | 0 | 0 | 0 | 0 | 500K | 0 | -572.59K | 0 | -1M | 0 |
Cash generated by investing activities | 0 | -13K | -22K | -7K | 528K | -180K | 378.78K | -38.68K | -1.32M | -30.68K |
Financing activities | ||||||||||
Common Stock Issued | 137.85M | 14.10M | 0 | 53.72M | 14.48M | 16.5M | 25.00M | -7.78B | 1.43M | 10.72M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | -120 | 0 | 0 | 0 | 0 | -7.78M | 0 | 0 |
Repayments of term debt | 0 | 0 | -8K | -17K | -2K | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 180.01M | 14.09M | -128K | 53.72M | 14.48M | 17.82M | 23.94M | 10.76M | 9.15M | 11.20M |
Net Change In Cash | 155.07M | -6.70M | -27.92M | 28.49M | -2.36M | 5.96M | 14.37M | -2.76M | -2.46M | 6.68M |
Cash at end of period | 169.68M | 14.60M | 21.30M | 49.22M | 20.73M | 23.09M | 17.09M | 2.72M | 5.49M | 7.95M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |